MedTrace Logo

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

NCT07136285 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-12-03

No results posted yet for this study

Summary

Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC

Conditions

  • SCLC, Extensive Stage

Interventions

DRUG

Olvi-Vec

Olvi-Vec will be administered to patient for 3 days during C1

DRUG

platinum (cisplatin or carboplatin)

After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Platinum （Carboplatin or Cisplatin）will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.

DRUG

Etoposide

After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Etoposide will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.

Sponsors & Collaborators

  • Genelux Corporation

    collaborator INDUSTRY

  • Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-24
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07136285 on ClinicalTrials.gov